Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 757 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Having Cancer as a Young Adult Put Me on a Path... May 25, 2021 ESMO Announces 2026 Fellowship Recipients Supporting Innovation in Cancer Research, Artificial... September 1, 2026 Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Teen Created App To Help His Non-Verbal Sister And Others Like... October 28, 2021 Load more HOT NEWS One year on: How has COVID-19 affected cancer services? EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab Study Suggests Watching Disney Movies May Improve Quality of Life for... How Do Black People with Cancer View Clinical Research?
